

NAMSDL



National Alliance for Model State Drug Laws

TABLE OF SYNTHETIC CANNABINOIDS BILLS, STATUTES & REGULATIONS

© 2011 Research is current as of February 25, 2011. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namSDL.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

The following table illustrates what the states are doing with regard to scheduling the five substances under review by the DEA and, where indicated, which states have already scheduled the substances by statute (S) or regulation (R).

	<u>JWH-018</u> ¹	<u>JWH-073</u> ²	<u>JWH-200</u> ³	<u>CP 47,497</u> ⁴	<u>homologues</u> ⁵	<u>cannabicyclohexanol</u> ⁶
Alabama	X (S)	X (S)				
Alaska	X	X	X	X	X	
Arizona	X	X	X	X		X
Arkansas ⁷	X (R)	X (R)	X	X		X
California						
Colorado	X	X	X	X	X	
Connecticut	X	X	X			
Delaware	X	X	X	X	X	
District of Columbia						
Florida	X	X	X	X	X	

¹ 1-pentyl-3-(1-naphthoyl)indole; naphthalen-1-yl-(1-pentylindol-3-yl)methanone

² 1-butyl-3-(1-naphthoyl)indole; naphthalene-1-yl-(1-butylyndol-3-yl)methanone

³ 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole; 1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethanone; [1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]-1-naphthalenyl-methanone

⁴ 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol; 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol; [2-(3-hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol; 5-(1,1-dimethylheptyl)-2-[3-hydroxycyclohexyl]-phenol; 2-(3-hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol

⁵ Homologues of CP 47,497 – referred to as the C6, C7, C8 or C9 homologues and also the dimethylhexyl, dimethyloctyl or dimethylnonyl homologues

⁶ 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol; This is also known as the C8 or dimethyloctyl homologue of CP 47,497

⁷ The Arkansas Board of Health adopted regulation on October 31, 2010 to schedule JWH-018, JWH-073, and others.

Georgia	X (S)		X	X (S)		
Hawaii	X	X		X	X	X
Idaho ⁸	X (R)	X (R)	X (R)	X (R)	X (R)	
Illinois	X (S)	X (S)	X	X	X	X
Indiana	X	X	X	X	X	
Iowa ⁹	X (R)	X (R)	X	X (R)	X (R)	X
Kansas ¹⁰	X (S)	X (S)				
Kentucky	X (S)	X (S)		X (S)		
Louisiana	X (S)	X (S)		X (S)	X (S)	
Maine						
Maryland	X	X	X	X	X	
Massachusetts						
Michigan	X (S)	X (S)	X (S)	X (S)	X (S)	
Minnesota ¹¹	X (R)	X (R)	X (R)	X (R)		
Mississippi ¹²	X (S)	X (S)	X (S)	X (S)	X (S)	
Missouri	X (S)	X (S)	X	X (S)	X (S)	X

⁸ The Idaho Board of Pharmacy adopted a temporary rule on November 3, 2010 to schedule JWH-018, JWH-073, CP 47,497, its homologues and others.

⁹ The Iowa Pharmacy Board scheduled JWH-018, JWH-073, CP 47,497, its homologues, and others, on an emergency basis on August 1, 2010.

¹⁰ Kansas is proposing to add the generic language from the ACMD report with minor changes.

¹¹ The Minnesota Board of Pharmacy proposed a rule on November 1, 2010 to schedule JWH-018, JWH-073, JWH-200, CP 47,497 and others.

¹² Mississippi is seeking to modify the current statute to include the generic language from the ACMD report with the associated synthetic substances classified under each definition.

Montana ¹³	X	X	X	X	X	
Nebraska ¹⁴						
Nevada ¹⁵	X (R)	X (R)	X (R)	X (R)	X (R)	
New Hampshire	X	X		X		
New Jersey	X	X				
New Mexico	X	X	X	X	X	X
New York	X	X		X		
North Carolina ¹⁶	X	X	X	X	X	X
North Dakota ¹⁷	X (R)	X (R)	X (R)	X (R)	X (R)	X
Ohio	X	X				
Oklahoma ¹⁸	X (S)	X (S)	X	X	X	
Oregon ¹⁹	X	X	X	X	X	
Pennsylvania	X	X	X	X		
Rhode Island ²⁰						

¹³ Montana is proposing to add the generic language from the ACMD report without the group classification names.

¹⁴ Nebraska has a proposed bill to schedule synthetic cannabinoids generally without specifying chemical designations, trade or other names. Nebraska is also proposing to add the generic language from the ACMD report with some changes.

¹⁵ The Nevada Board of Pharmacy has proposed regulation to schedule JWH-018, JWH-073, JWH-200, CP 47,497, its homologues, plus others.

¹⁶ North Carolina seeks to add the generic language from the ACMD report and cites all five substances as trade or other names under the appropriate group classification name (i.e., JWH-018, JWH-073, JWH-200 under naphthoylindoles).

¹⁷ The North Dakota Board of Pharmacy scheduled JWH-018, JWH-073, the AK version of CP 47,497, its homologues and others on February 26, 2010.

¹⁸ Oklahoma is seeking to add the generic language from the ACMD report as well as a list of the trade names included in the report.

¹⁹ The Oregon Board of Pharmacy temporarily scheduled JWH-018, JWH-073, a different version of JWH-200, different version of CP 47,497, its homologues and others on an emergency basis on November 1, 2010.

²⁰ Rhode Island has a proposed bill to schedule synthetic cannabinoids generally without specifying chemical designation, trade or other names.

South Carolina	X	X	X	X		X
South Dakota	X	X	X	X		X
Tennessee	X (S)	X (S)	X	X		X
Texas ²¹	X	X	X	X	X	
Utah	X	X	X	X	X	
Vermont						
Virginia	X	X	X	X	X	
Washington ²²	X	X	X	X	X	
West Virginia	X	X	X	X	X	
Wisconsin						
Wyoming	X	X		X		

(S) = Substances scheduled by statute

(R) = Substances scheduled or proposed to be scheduled by regulation

²¹ Texas is seeking to add the generic language from the ACMD report as well as a list of the trade names included in the report.

²² The Washington Department of Health scheduled JWH-018, JWH-073, JWH-200, CP 47,497 and its homologues on an emergency basis on February 2, 2011.

© 2011 Research is current as of February 25, 2011. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.